7 years, not that!SOLO-1 research OS data debut ESMO-Ora Pali "maintains" long survival, the prospects are expected

*For medical professionals for reading reference

Ovarian cancer has maintained OS for 7 years! And, not only there!

The announcement of the results of SOLO-1 research promoted the treatment indications for the first-tier ovarian cancer of Olapali, and changed the treatment model of patients with advanced ovarian cancer. At the annual meeting of the European Cancer Internal Science Society (ESMO) in 2020, its five -year follow -up data was announced, setting a "longest PFS" record for the first line of ovarian cancer in polyllinnosine dilate, a PARPI cancer. Cancer -sensitive gene mutations (BRCAM) patients with advanced ovarian cancer saw the hope of "clinical cure". Just two years later, the seven-year follow-up data of Solo-1 studies appeared on ESMO. Ovarian cancer's front-line maintenance OS achieved breakthroughs again, amazing the world. On this opportunity, "Medical Community" specially invited Professor Wu Xiaohua at the Department of Oncology, Cancer Hospital Affiliated to Fudan University, Professor Northern Huacheng, Department of Obstetrics and Gynecology at Qilu Hospital of Shandong University to analyze in-depth analysis of the treatment strategies of the first-tier treatment of patients with advanced ovarian cancer and SOLO-1 studies in 7 years. Major value of data update. Don't miss it!

Parpi front -line maintenance treatment -Patient chemotherapy is the best choice for patients to obtain "long survival"

As early as 2005, two articles published in Nature Magazine have confirmed that there is a "synthesis of death" effect between Parpi and BRCAM, indicating that BRCAM tumors are more sensitive to Parpi treatment. Since then, PARPI has been formally used in the field of tumor treatment. In the following years, Parpi represented by Olapali was successful in the clinical study of phase I and phase II in the treatment of BRCAM ovarian cancer. Two items published by the ESMO Annual Conference 2018 and 2019 are targeted at the first-line maintenance treatment related to BRCAM and HRD (+) new diagnosis of advanced ovarian cancer patients (solo-1 research [1], PAOLA-1 study [2]), so that to make Patients with advanced ovarian cancer entered a new model of "surgery+chemotherapy+maintenance treatment", and successfully rewritten the treatment pattern of patients with advanced ovarian cancer.

Figure 1 SOLO-1 Study and PAOLA-1 Study

Professor Kong Beihua said that after the first announcement of solo-1 research data in 2018, the main line of Alapali's front-line maintenance can significantly improve the survival time (PFS) of patients' no disease, and significantly reduce the risk of disease progress and death. At the SULO-1 research update data reported by Professor Susana Banerjee in the following 2020 ESMO Annual Conference, we further saw the PFS compared to the PFS compared to the Alapari group (56.0 VS 13.8 months, HR = 0.3333 , 95%CI: 0.25 ~ 0.43). For patients who have reached a complete alleviating (CR), that is, patients with low clinical recurrence risk and good prognosis, Orapari has significantly reduced the risk of disease recurrence and death by 67%than the placebo group. In the past 5 years, 48%of the Aurapari group still had no progress in the group, almost doubled in the placebo group [3]. Professor Kong Beihua emphasized that in this study, the survival benefits brought by Olapali can still last for a long time after two years of treatment, which allows patients with advanced ovarian cancer in BRCAM to see standard surgery and chemotherapy after chemotherapy Relying the standard for maintenance of the norms may obtain the hope of "clinical healing". At present, Ora Pali has become a recommended standard for the first -line treatment standard for patients with advanced patients in BRAC mutations in ovarian cancer diagnosis and treatment at home and abroad.

Figure 2 SOLO-1 Study 5-year follow-up data

With the announcement of the two SOLO-1 research data above, Ora Pali brings a veritable "long" PFS, which is also more exciting: whether the Alapali front-line maintenance can bring more lasting treatment The benefit of the overall survival (OS)?

Solo-1 research OS data update-7 years follow-up shows the "longest" survival benefit

At this year's ESMO Annual Meeting, Solo-1 studied for 7 years of long-term follow-up data [4]. Research data shows:

After 7 years of follow -up, the Olapali treatment group's OS has not yet reached, showing a significant advantage over the 75.2 months of the placebo group. At the same time, it is worth mentioning that in the control group patients, 44.3%of subsequent treatment uses Parpi and benefits from it.

Compared with the placebo group, the risk of death of Olapali maintenance groups decreased by 45%(the Olapal group MOS did not reach the VS control group 75.2 months HR 0.55; 95%CI 0.40-0.76; P = 0.0004) Essence

As of the end of the 7 years, 67%of the Alapari maintenance treatment group survived, and this proportion was 46.5%in the control group.

In terms of security, after the 7 -year follow -up, Ora Pali maintained the safety of the treatment group and the previous report. No new security signals were found.

The announcement of SOLO-1 research for 7 years of long-term follow-up data has a milestone in the field of ovarian cancer treatment. It is also another evidence for Olapali as a preferred strategy for the treatment of treatment as a patient with advanced ovarian cancer. Professor Wu Xiaohua emphasized: "7 years of follow -up is rare. This is by far PARPI for the treatment of patients with advanced ovarian cancer. The longest tracking time in related research. Many anti -tumor treatment, in a short treatment time window,, in a short treatment time window, in the window of a short treatment time, in the window of a short treatment time, in the window of a short treatment time, in the window of a short treatment time, in the window of a short treatment time, in the window of a short treatment time, in the window of a short treatment time, in the window of a short treatment time, in the window, It may be possible that patients have obtained better tumor control and even fully alleviated, but they cannot bring satisfactory results in the improvement of the most concerned survival time for patients. In the 7 years, the survival data brought by the patients who follow the group will adhere to the follow -up group. The gold content is self -evident. "Professor Wu Xiaohua interpreted the significant value of the OS data published in detail. He said that the updated SOLO-1 research OS data, Ora Pali has achieved the longest OS data so far. After 88 months of follow-up, the patient has not reached the median OS data. Compared with the placebo group Show a significant advantage. At the same time, Ora Pali maintained the treatment of patients' deaths by 45%. After 7 years, 67%of patients survived. It is not difficult to see that the survival benefits brought by the 2 -year Orapari maintenance treatment have continued to exist within a few years after the treatment. "Long survival".

In addition, Professor Kong Beihua added that it is worth noting that 47%of patients have survived for 7 years in the control group, of which nearly half of the patients received subsequent treatment of Parpi and benefited from it. Essence In terms of Olapari maintenance treatment, Professor Kong Beihua said that in a 7 -year follow -up observation, the Ora Pali treatment group did not discover a new safety signal, which is enough to prove that the first -line maintenance treatment of advanced ovarian cancer is maintained. Lapari is a patient's choice of long -term survival safety and effective treatment.

Break the "three 70%" treatment spell -help patients "live longer and live better"

"70%of the patients with ovarian cancer are late and after the initial treatment is relieved, and about 70%of patients will recur within 3 years, and 70%of patients with ovarian cancer have survived for less than 5 years." These three 70%are like curses. Generally, the hearts of medicalists in the field of gynecological tumors are lingering. Professor Wu Xiaohua told us the "helplessness" experienced by many ovarian cancer patients. He said that the treatment mode of patients with ovarian cancer is mainly surgery and supplemented by platinum drug chemotherapy strategies. Before PARPI failed to be used in clinical treatment, most patients with ovarian cancer will go through the terrible "cycle" of surgery, chemotherapy, relapse, re -recurrence, re -recurrence, and re -chemotherapy. In this natural course of ovarian cancer, due to the gradual decrease in chemotherapy sensitivity, the recurrence cycle continues to shorten, and will eventually develop into platinum chemotherapy resistance. The patient's body and psychology will accept double torture. Therefore, the time when patients have stable patients after the first -line chemotherapy can be extended as possible, becoming an important time window for patients with ovarian cancer to achieve "clinical cure".

From the first announcement of SOLO-1 research data on ESMO in 2018, the academic community has been looking forward to the "miracle" of Olapal's "miracles" for the maintenance treatment of advanced ovarian cancer. Solo-1 research PFS data update in 2020 is amazing global, and this year's ESMO annual meeting announced the OS data obtained for 7 years of follow-up, which is the moment of "healing dreams and reality". After 88 months of follow -up, the median OS data has not been reached, 7 years, not only there! SOLO-1 research successfully brought Olapari into the front line of advanced ovarian cancer, which can be described as redefining the treatment model of patients with advanced ovarian cancer. At present, as the 1 -category recommendation standard for the first -line treatment of patients with advanced ovarian cancer patients in the BRAC mutation, Olapali is helping more advanced ovarian cancer patients "live longer and live better" to be more Chinese ovarian cancer patients Bring the hope of clinical cure.

*Expert sorting in the order of surname

Expert Introduction

Professor Kong Beihua

Shandong University's first -level special professor and doctoral supervisor

Director of the Obstetrics and Gynecology and Research Office of Qilu Hospital of Shandong University

Special experts, teaching teachers, and leaders of health systems in Taishan scholars in Shandong Province

National Health and Health Commission and Shandong Province outstanding contribution expert

State Council special allowance expert

Chairman of the Gynecological Oncology Branch of the Chinese Medical Association

Deputy Chairman of the Obstetrics and Gynecology Branch of the Chinese Medical Association

Vice President of the Obstetrics and Gynecology Branch of the Chinese Medical Medical Association

Deputy Chairman of the National Practice Physician Qualification Examination Clinical Medicine Examination Committee

Deputy Chief Editor of Chinese Women's Magazine

Editor -in -chief of Modern Obstetrics and Gynecology Magazine

National Planning Teaching Material "Obstetrics and Gynecology" Ninth Edition Second Editor

Representative of the Eleventh National People's Congress

Expert Introduction

Professor Wu Xiaohua

Director of the Department of Women's Tumor, Medical Doctor, Professor, and Doctoral Tutor of the Cancer Hospital Affiliated to Fudan University

Chief Expert of Gynecological Oncology Multi -disciplinary Treatment Group

Shanghai Excellent Discipline Leader, Shanghai Medical Leading Talent

The current chairman of the Gynecology and Cancer Professional Committee of the China Anti -Cancer Association

Standing Committee Member of the Chinese Medical Association Gynecology and Cancer Professional Committee

Director of the China Clinical Oncology Society (CSCO)

Chairman of the Shanghai Anti -Cancer Association and Chairman of the Gynecological Cancer Professional Committee

Former member of the International Women's Cancer Society (IGCS) Education Commission and candidate for directors of the Asia -Pacific region

Former member of the International Committee of the American Gynecological Oncology Society (SGO) International Committee of Fernberg Medical Department of Northwestern University

Currently serving as the International Journal of Gynecological Cancer, Cancer Medicine, Journal of Gynecology Oncology, Chinese Gynecological Magazine, China Anatomy and Clinical Magazine and other magazines.

The clinical guidelines for NCCN cervical cancer and endometrial cancer resource layer diagnosis and treatment (NCCN Framework) review expert

references:

[1] .moore k, et al. Maintenance Olaparib in Patients with Newly Diagnosed Ovarian Cancer.n English. 2018; 379 (26): 2495-2505.

[2].Isabelle L. , et al. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum- Based Chemotherapy (PCH) Plus Bev 2019 ESMO, abstract: lba2_pr

[3] .sana Banerjee, et al. Maintenance Olaparib for Patients (PTS) with newly diagnosed, Advanced Ovarian Cancer (OC) and A BRCA Mutation (BRCAM): 5-year follow-up (f/up) Solo12020 ESMO, ABSTRACT: 811Mo

[4]. Paul Disilvesstro, et al. Overall Survival (OS) at 7-Year (y) follow-up (f/u) in Patients (PTS) with newly diagnosed ovarian can (OC) and A BRCAMATATAMM (AC) ) WHO Received Maintenance Olaparib in The Solo1/GOG-3004 TRIAL

*This article is only used to provide scientific information to medical people, and does not represent the viewpoint of this platform

- END -